Go Pro
NASDAQ:SRTS

Sensus Healthcare (SRTS) Stock Price, News & Analysis

Sensus Healthcare logo
$3.09 +0.02 (+0.65%)
As of 04:00 PM Eastern

About Sensus Healthcare Stock (NASDAQ:SRTS)

Advanced

Key Stats

Today's Range
$3.04
$3.14
50-Day Range
$2.69
$3.10
52-Week Range
$2.66
$5.49
Volume
10,615 shs
Average Volume
18,565 shs
Market Capitalization
$50.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.17
Consensus Rating
Moderate Buy

Company Overview

Sensus Healthcare, Inc. is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls. These systems allow dermatologists and radiation oncologists to administer precise doses of radiation directly to lesions while sparing surrounding healthy tissue. In addition to its hardware, Sensus Healthcare offers training, credentialing support and treatment planning assistance, helping clinics and hospitals integrate SRT into their service offerings and meet regulatory requirements.

Founded in 2004 and headquartered in Jacksonville, Florida, Sensus Healthcare has built a network of clinical partners and distributors across the United States and select international markets. The company’s sales and service organization works closely with dermatology practices, oncology centers and academic institutions to facilitate device installation, maintenance and ongoing technical support. Over time, Sensus Healthcare has expanded its outreach through strategic collaborations with key opinion leaders and specialty societies to raise awareness of superficial radiation therapy protocols and best practices.

Under the leadership of President and CEO R. Scott Ruskin, Sensus Healthcare continues to pursue research and development initiatives aimed at broadening the clinical applications of its SRT technology. The company remains focused on generating long-term data on treatment efficacy and patient outcomes, while exploring opportunities to enhance device capabilities and workflow integration. With a growing installed base and a commitment to education and clinical validation, Sensus Healthcare positions itself as a dedicated provider of non-invasive radiation therapy solutions for dermatology and oncology practitioners.

AI Generated. May Contain Errors.

Sensus Healthcare Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

SRTS MarketRank™: 

Sensus Healthcare scored higher than 39% of companies evaluated by MarketBeat, and ranked 654th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sensus Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Sensus Healthcare has a consensus price target of $7.17, representing about 131.9% upside from its current price of $3.09.

  • Amount of Analyst Coverage

    Sensus Healthcare has only been the subject of 1 research reports in the past 90 days.

  • Read more about Sensus Healthcare's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sensus Healthcare is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sensus Healthcare is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sensus Healthcare has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sensus Healthcare's valuation and earnings.
  • Percentage of Shares Shorted

    1.37% of the float of Sensus Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Sensus Healthcare has a short interest ratio ("days to cover") of 8.49.
  • Change versus previous month

    Short interest in Sensus Healthcare has recently increased by 0.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sensus Healthcare does not currently pay a dividend.

  • Dividend Growth

    Sensus Healthcare does not have a long track record of dividend growth.

  • Search Interest

    2 people have searched for SRTS on MarketBeat in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $4,995.00 in company stock, which represents 0.0098% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Sensus Healthcare insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,995.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.20% of the stock of Sensus Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    25.30% of the stock of Sensus Healthcare is held by institutions.

  • Read more about Sensus Healthcare's insider trading history.
Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRTS Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

SRTS Stock Analysis - Frequently Asked Questions

Sensus Healthcare's stock was trading at $3.98 at the beginning of the year. Since then, SRTS stock has decreased by 22.4% and is now trading at $3.09.

Sensus Healthcare, Inc. (NASDAQ:SRTS) announced its earnings results on Thursday, May, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.04. The business had revenue of $3.39 million for the quarter, compared to analysts' expectations of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative trailing twelve-month return on equity of 15.79%.
Read the conference call transcript
.

Sensus Healthcare (SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

Sensus Healthcare's top institutional shareholders include Bank of New York Mellon Corp (0.61%) and BlackRock Inc. (0.51%). Insiders that own company stock include Joseph C Sardano, Eric Sachetta, Michael Sardano and John Heinrich.
View institutional ownership trends
.

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sensus Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD), EMCOR Group (EME), e.l.f. Beauty (ELF) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/07/2026
Today
8/10/2026
Next Earnings (Confirmed)
8/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:SRTS
CIK
1494891
Employees
40
Year Founded
2010

Price Target and Rating

High Price Target
$8.00
Low Price Target
$6.00
Potential Upside/Downside
+131.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.72 million
Net Margins
-34.50%
Pretax Margin
-50.57%
Return on Equity
-15.79%
Return on Assets
-14.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.27
Quick Ratio
4.03

Sales & Book Value

Annual Sales
$27.48 million
Price / Sales
1.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.93 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
16,460,000
Free Float
14,783,000
Market Cap
$50.86 million
Optionable
Optionable
Beta
1.10

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:SRTS) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners